{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:07:34Z","timestamp":1787933254115,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ymgme.2024.108512","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:21:11Z","timestamp":1717676471000},"page":"108512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses"],"prefix":"10.1016","volume":"142","author":[{"given":"Julie","family":"Kissell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Rochmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Minini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krupnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.108512_bb0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0925-4439(99)00074-5","article-title":"Biochemical consequences of mutations causing the GM2 gangliosidoses","volume":"1455","author":"Mahuran","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2024.108512_bb0010","article-title":"The GM2 gangliosidoses: unlocking the mysteries of pathogenesis and treatment","volume":"136195","author":"Toro","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2024.108512_bb0015","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"The GM2 gangliosidoses","author":"Gravel","year":"2019"},{"key":"10.1016\/j.ymgme.2024.108512_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.GIM.0000154300.84107.75","article-title":"Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients","volume":"7","author":"Neudorfer","year":"2005","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108512_bb0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ana.25689","article-title":"Natural history of adult patients with GM2 Gangliosidosis","volume":"87","author":"Masingue","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2024.108512_bb0030","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00415-019-09364-3","article-title":"Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease","volume":"266","author":"Jahnov\u00e1","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2024.108512_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-020-01354-3","article-title":"Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases","volume":"15","author":"Lyn","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.ymgme.2024.108512_bb0040","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1007\/s10545-010-9186-3","article-title":"Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up","volume":"33","author":"Masciullo","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108512_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","article-title":"Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment","volume":"11","author":"Shapiro","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108512_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108512_bb0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13023-015-0260-7","article-title":"Effect of cyclic, low dose pyrimethamine treatment in patients with late onset Tay Sachs: an open label, extended pilot study","volume":"10","author":"Osher","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108512_bb0060","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2024.108512_bb0065","series-title":"Rare Diseases: Natural History Studies for Drug Development Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.ymgme.2024.108512_bb0070","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1740774512438980","article-title":"National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods","volume":"vol. 9","author":"Grinnon","year":"2012","journal-title":"Clin. Trials (Lond., Engl.)"},{"key":"10.1016\/j.ymgme.2024.108512_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jnnp.2006.096008","article-title":"How is disease progress in Friedreich's ataxia best measured? A study of four rating scales","volume":"78","author":"Fahey","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgme.2024.108512_bb0080","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","article-title":"Measuring Friedreich ataxia: complementary features of examination and performance measures","volume":"66","author":"Lynch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2024.108512_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/153944928500500102","article-title":"Adult norms for the nine hole peg test of finger dexterity","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"Occup. Ther. J. Res."},{"key":"10.1016\/j.ymgme.2024.108512_bb0090","series-title":"Assessment of Intelligibility of Dysarthric Speech, Austin, TX","author":"Yorkston","year":"1984"},{"key":"10.1016\/j.ymgme.2024.108512_bb0095","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.apmr.2019.08.488","article-title":"Quantitative synthesis of timed 25-foot walk performance in multiple sclerosis","volume":"101","author":"Sikes","year":"2020","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ymgme.2024.108512_bb0100","series-title":"Eye Movement Abnormalities Are Ubiquitous in the Spinocerebellar Ataxias Cerebellum (London, England)","first-page":"1130","volume":"vol. 18","author":"Stephen","year":"2019"},{"key":"10.1016\/j.ymgme.2024.108512_bb0105","first-page":"387","article-title":"Balance in elderly patients: the \u201cget-up and go\u201d test","volume":"67","author":"Mathias","year":"1986","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ymgme.2024.108512_bb0110","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/mds.22681","article-title":"Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS","volume":"24","author":"Schmahmann","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2024.108512_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/NPT.0b013e3181a33638","article-title":"Relationships and responsiveness of six upper extremity function tests during the first six months of recovery after stroke","volume":"33","author":"Beebe","year":"2009","journal-title":"J. Neurol. Phys. Ther."},{"key":"10.1016\/j.ymgme.2024.108512_bb0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acn3.332","article-title":"Progression of Friedreich ataxia: quantitative characterization over 5 years","volume":"3","author":"Patel","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2024.108512_bb0125","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/01.wnl.0000436065.97642.d2","article-title":"Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world","volume":"81","author":"Goldman","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2024.108512_bb0130","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1212\/WNL.0000000000008959","article-title":"Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis","volume":"94","author":"Stephen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2024.108512_bb0135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10545-008-0884-z","article-title":"Neurocognitive testing in late-onset Tay-Sachs disease: a pilot study","volume":"31","author":"Elstein","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108512_bb0140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/hed.10095","article-title":"Impact of palatal prosthodontic intervention on communication performance of patients' maxillectomy defects: a multilevel outcome study","volume":"24","author":"Sullivan","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.ymgme.2024.108512_bb0145","first-page":"143","article-title":"Rate reduction methods for improving speech intelligibility of dysarthric speakers with Parkinson\u2019s disease","volume":"6","author":"Dagenais","year":"1998","journal-title":"J. Speech Lang. Hear. Res."},{"key":"10.1016\/j.ymgme.2024.108512_bb0150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1044\/jshr.3802.304","article-title":"Intelligibility and phonetic contrast errors in highly intelligible speakers with amyotrophic lateral sclerosis","volume":"38","author":"Riddel","year":"1995","journal-title":"J. Speech Hear. Res."},{"key":"10.1016\/j.ymgme.2024.108512_bb0155","series-title":"Changes in Maximum Capacity Tongue Function following the Lee Silverman Voice Treatment Program","first-page":"331","volume":"8","author":"Ward","year":"2000"},{"key":"10.1016\/j.ymgme.2024.108512_bb0160","first-page":"1","article-title":"Effects of speaking rate on word recognition in Parkinson's disease and normal aging","volume":"6","author":"Forrest","year":"1998","journal-title":"J. Med. Speech-Language Pathol."},{"key":"10.1016\/j.ymgme.2024.108512_bb0165","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/21678421.2013.817585","article-title":"Bulbar and speech motor assessment in ALS: Challenges and future directions","volume":"14","author":"Green","year":"2013","journal-title":"Amyotroph. Lateral Sclerosis Frontotemp. Degen."},{"key":"10.1016\/j.ymgme.2024.108512_bb0170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ymgme.2021.06.008","article-title":"Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis","volume":"133","author":"Rowe","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108512_bb0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/acn3.51947","article-title":"Clinical and imaging predictors of late-onset GM2 gangliosidosis: A scoping review","author":"Godbole","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2024.108512_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12984-019-0490-3","article-title":"Quantitative assessment of cerebellar ataxia, through automated limb functional tests","volume":"16","author":"Krishna","year":"2019","journal-title":"J. Neuroeng. Rehabil."},{"key":"10.1016\/j.ymgme.2024.108512_bb0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/21678707.2018.1449638","article-title":"Clinical trial design for Friedreich ataxia - where are we now and what do we need?","volume":"6","author":"Rummey","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2024.108512_bb0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clinbiochem.2007.12.026","article-title":"Simultaneous quantification of GM1 and GM2 gangliosides by isotope dilution tandem mass spectrometry","volume":"41","author":"Gu","year":"2008","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2024.108512_bb0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2021.08.009","article-title":"Natural history of Tay-Sachs disease in sheep","volume":"134","author":"Story","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108512_bb0200","article-title":"Chitotriosidase as a biomarker for gangliosidoses","volume":"29","author":"Kim","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2024.108512_bb0205","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.expneurol.2014.09.020","article-title":"Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease","volume":"263","author":"Bradbury","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2024.108512_bb0210","doi-asserted-by":"crossref","first-page":"e29074","DOI":"10.1371\/journal.pone.0029074","article-title":"Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease","volume":"6","author":"Kodama","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2024.108512_bb0215","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","article-title":"Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale","volume":"64","author":"Subramony","year":"2005","journal-title":"Neurology"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224003962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224003962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:40:00Z","timestamp":1720611600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224003962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1096719224003962"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108512","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108512"}}